Biofrontera Inc. (BFRIW) stock
BFRIWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BFRI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.00+0.00 (0.00%)
Close on Oct 30, 2026Market cap $12.96MP/E –Yield –
Biofrontera revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Biofrontera's revenue for the twelve months ending Jun 30, 2026 was $46.18M, up 17.8% year over year. For fiscal 2025 it was $41.71M, up 11.7% from the year before. The highest annual figure on record is $41.71M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.71M | +11.7% |
| FY2024 | Dec 31, 2024 | $37.32M | +9.5% |
| FY2023 | Dec 31, 2023 | $34.07M | +18.8% |
| FY2022 | Dec 31, 2022 | $28.67M | +19.0% |
| FY2021 | Dec 31, 2021 | $24.10M | +27.9% |
| FY2020 | Dec 31, 2020 | $18.85M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $12.00M | +32.9% |
| Q1 FY2026 | Mar 31, 2026 | $10.08M | +17.4% |
| Q4 FY2025 | Dec 31, 2025 | $17.10M | +36.2% |
| Q3 FY2025 | Sep 30, 2025 | $6.99M | -22.5% |
| Q2 FY2025 | Jun 30, 2025 | $9.03M | +15.2% |
| Q1 FY2025 | Mar 31, 2025 | $8.59M | +8.5% |
| Q4 FY2024 | Dec 31, 2024 | $12.56M | +18.5% |
| Q3 FY2024 | Sep 30, 2024 | $9.01M | +1.3% |
| Q2 FY2024 | Jun 30, 2024 | $7.84M | +34.0% |
| Q1 FY2024 | Mar 31, 2024 | $7.91M | -9.4% |
| Q4 FY2023 | Dec 31, 2023 | $10.60M | +4.5% |
| Q3 FY2023 | Sep 30, 2023 | $8.90M | +105.8% |
| Q2 FY2023 | Jun 30, 2023 | $5.85M | +31.2% |
| Q1 FY2023 | Mar 31, 2023 | $8.73M | -10.4% |
| Q4 FY2022 | Dec 31, 2022 | $10.14M | +10.6% |
| Q3 FY2022 | Sep 30, 2022 | $4.32M | -0.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.46M | -23.9% |
| Q1 FY2022 | Mar 31, 2022 | $9.75M | +105.5% |
| Q4 FY2021 | Dec 31, 2021 | $9.17M | +7.0% |
| Q3 FY2021 | Sep 30, 2021 | $4.33M | +33.3% |
| Q2 FY2021 | Jun 30, 2021 | $5.86M | – |
| Q1 FY2021 | Mar 31, 2021 | $4.74M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.57M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.25M | – |